Mechanisms of pathological VEGF production in the retina and modification with VEGF-antagonists

Studies on Retinal and Choroidal Disorders

Volumn , Issue , 2012, Pages 277-305

  Klettner, Alexa ^a   Roider, Johann ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979076558     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-606-7_13     Document Type: Chapter

References (175)

1. Carmeliet P, Ferriera V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
2. Miquerol L, Langille BL, Nagy A (2000) Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-3946.
3. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
4. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Comm 161:851-858.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
6. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954.
7. 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272:7151-7158.
8. 148 mRNA, a novel truncated splice variant. Clin Sci 97:303-312.
9. 183. Biochim Biophys Acta 1443:400-406.
10. 111 is induced by genotoxic agents. J Cell Biol 179:1261-1273.
11. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691.
12. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
13. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix bound VEGF. Mol Biol Cell 4:1317-1326.
14. Ferrara A (2010) Binding to the expracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 21:687-690.
15. Klettner A, Roider J (2009) Treating age-related macular degeneration-interaction of VEGF-antagonists with their target. Mini Rev Med Chem 9:1127-1135.
16. Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP (1999) Constitutive expression of VEGF, VEGFR-1, and VEGF-2 in normal eyes. Invest Ophthalmol Vis Sci 40:2115-2121.
17. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M (1998) Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 152:1453-1462.
18. 183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 40:752-759.
19. 165b, an inhibitory splice variant of VEGF, is down regulated in renal cell carcinoma. Canc Res 62:4123-4131.
20. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones R, Cui TG, Sugiono M, Waine E, Perring R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO (2004) VEGF165b, an inhibitory VEGF splice variant:mechanisms of action, in vivo effects on angiogenesis and endogenous protein expression. Cancer Res 64:7822-7835.
21. 165b inhibits experimental choriodal neovascularization. Invest Ophthalmol Vis Sci 51:4282-4288.
22. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factor. J Cell Sci 121:3487-3495.
23. Giacca M (2010) Non-redundant functions of the protein isoforms arising from alternative splicing of the VEGF-A pre-mRNA. Transcription 1:149-153.
24. Elias AP, Dias S (2008) Microenviroment changes (in pH) affect VEGF alternative splicing. Cancer Microenviron 1:131-139.
25. Qin G, Kishore R, Dolan CM, Silver M, Wecker A, Luedemann CN, Thorne T, Hanley A, Curry C, Heyd L, Dinesh D, Kearney M, Martelli F, Murayama T, Goukassian DA, Zhu Y, Losorde DW (2006) Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci USA 103:11015-11020.
26. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B (2010) The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29:5392-5403.
27. Bastide A, Karaa Z, Bornes S, Hieblot C, Lacazette E, Prats H, Touriol C (2008) An upstream open reading frame with an IRES control expression of a specific VEGF-A isoform. Nucleic Acids Res 36:2434-2445.
28. Gogat K, Le Gat L, Van Den Berghe L, Marchant D, Kobetz A, Gadin S, Gasser B, Quere I, Abitbol M, Menasche M (2004) VEGF and KDR gene expression during human embryonic and fetal eye development. Invest Ophthalmol Vis Sci 45:7-14.
29. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E (1995) Development of retina vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738-4747.
30. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3 ¢ kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
31. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA (2009) An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106:18751-18756.
32. Gora-Kupilas K, Josko J (2005) The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43:31-39.
33. Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function and therapeutic potential. Neurosignals 14:207-221.
34. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67.
35. Byeon SH, Lee SC, Choi SH, Lee HK, Lee JH, Chu YK, Kwon OW (2010) Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci 51:1190-1197.
36. Kilic Ü, Kilic E, Järve A, Guo Z, Spudich A, Bieber K, Barzena U, Bassetti CL, Marti HH, Hermann DM (2006) Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating Erk1/2 and Akt pathways. J Neurosci 26:12439-12446.
37. Saint-Geniez M, Maharaj ASR, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA (2008) Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PloS One 3:e3554.
38. Ueno S, Pease ME, Wersinger DM, Masuda T, Vinores SA, Licht T, Zack DJ, Quigley H, Keshet E, Campochiaro PA (2008) Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217:13-22.
39. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permability factor: a tumor derived polypeptide that induces endothelia cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545.
40. 164 -mediated inflammation is required for pathological, but not physiological ischemiainduced retinal neovascularization. J Exp Med 198:483-489.
41. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167:1451-1459.
42. Le YZ, Bai Y, Zhu M, Zheng L (2010) Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature. J Neurochem 112:1584-1592.
43. Bai Y, Ma JX, Guo J, Wang J, Zhu M, Chen Y, Le YZ (2009) Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol 219:446-454.
44. Cervantes-Villagrana AR, Garcia-Roman J, Gonzales-Espinosa C, Lamas M (2010) Pharmacological inhibition of N -methyl d -aspartate receptor promotes secretion of vascular endothelial growth factor in müller cells: effects of hyperglycemia and hypoxia. Curr Eye Res 35:733-741.
45. Mowat FM, Luhmann UFO, Smith AJ, Lange C, Duran Y, Harten S, Shukla D, Maxwell PH, Ali RR, Bainbridge JWB (2010) HIF-1alpha and HIF-2alpha are differentially activated in distinct cell populations in retinal ischemia. PloS One 5:e11103.
46. Schrufer TL, Antonetti DA, Sonenberg N, Kimball S, Gardner TW, Jefferson LS (2010) Ablation of 4E-BP1/2 prevents hyperglycemia-mediated induction of VEGF expression in the rodent retina and in Müller cells in culture. Diabetes 59:2107-2116.
47. Scott A, Powner MB, Gandhi P, Clarkin C, Gutmann DH, Johnson RS, Ferrara N, Fruttiger M (2010) Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PloS One 5:e11863.
48. Weidemann A, Krohne TU, Aguilar E, Kurihara T, Takeda N, Dorrell MI, Simon MC, Haase VH, Friedlander M, Johnson RS (2010) Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 58:1177-1185.
49. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA (2003) Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:275-288.
50. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973-978.
51. Vidro EK, Gee S, Unda R, Ma JX, Tsin A (2008) Glucose and TGFbeta2 modulate the viability of cultured human retinal pericytes and their VEGF release. Curr Eye Res 33:984-993.
52. Amadio M, Bucolo C, Leggio GM, Drago F, Govoni S, Pascale A (2010) The PKCß/HuR/ VEGF pathway in diabetic retinopathy. Biochem Pharmacol 80:1230-1237.
53. Cao R, Xue Y, Hedlund EM, Zhong Z, Trisaris K, Tondelli B, Lucchini F, Zhu Z, Dissing S, Cao Y (2010) VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Nat Acad Sci 107:856-861.
54. Muller YA, Christinger HW, Keyt BA, de Vos AM (1997) The crystal structure of VEGF refined to 1.93 Angstrom resolution: multiple copy flexibility and receptor binding. Structure 5:1325-1338.
55. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709.
56. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS (2004) A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2:315-326.
57. Schenone S, Bondavalli F, Botta M (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 14:2495-2516.
58. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995.
59. Rahimi N (2006) VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 11:818-829.
60. Schwartz JD, Rowinski EK, Youssoufian H, Pytowski B, Wu Y (2010) Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antiobody targeting vascular endothelial growth factor receptor-1). Cancer 116:1027-1032.
61. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343.
62. Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Eye Res 312:549-560.
63. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravastation in pathological conditions. Nat Med 7:575-583.
64. Gille H, Kowaslki J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222-3230.
65. Schlessinger J, Lemmon MA (2003) SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003(191):R12.
66. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B (2010) Diabetic macula oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 88:279-291.
67. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M (1997) Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 19:547-559.
68. Muraga M, Fernandez-Capetillo O, Tosato G (2005) Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelia growth factor receptor-2. Blood 105:1992-1999.
69. Bachelder RE, Crago A, Chung J, Wendt MA, Shao LM, Robinson G, Mercurio AM (2001) Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61:5736-5740.
70. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D (2003) Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-dependent endothelial cell migration. J Biol Chem 278:48848-48860.
71. Grünewald FS, Prota AE, Giese A, Ballmer-Hofer K (2010) Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiongenic signaling. Biochim Biophys Acta 1804:567-580.
72. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G (1992) The binding of vascular endothelial growth factor to its receptor is dependent on cell surface-associated heparin-like molecules. J Biol Chem 267:6093-6098.
73. 121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271:5519-5523.
74. 121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270:11322-11326.
75. 165 KDR complexes. J Biol Chem 276:39748-39754.
76. Mamluk R, Gechtman Z, Kucher ME, Gasiunas N, Gallagher J, Klagsbrun M (2002) Neuropilin-1 binds vascular endothelial growth factor 165, placental growth factor-2 and heparin via its b1b2 domain. J Biol Chem 277:24818-24825.
77. Soker S, Svahn CM, Neufeld G (1993) Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 268:7685-7691.
78. 165. J Biol Chem 274:10816-10822.
79. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vesel branching morphogenesis. Genes Dev 16:2684-2698.
80. Akiri G, Nahari D, Finkelstein Y, Le SH, Elroy-Stein O, Levi BZ (1998) Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17:227-236.
81. Pages G, Pouyssegur J (2005) Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 65:564-573.
82. Hanson J, Gorman J, Reese J, Fraizer G (2007) Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci 12:2279-2290.
83. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613.
84. Milanini-Mongiat J, Pouyssegur J, Pages G (2002) Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 277:20631-20639.
85. Pages G (2007) Sp3-mediated VEGF regulation is dependent on phosphorylation by extracellular signals regulated kinases (Erk). J Cell Physiol 213:454-463.
86. Schäfer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Höcker M (2003) Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 278:8190-8198.
87. Yoo PS, Mulkeen AL, Cha CH (2006) Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 12:4937-4942.
88. Jang SK, Kräusslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E (1988) A segment of the 5 ¢ nontranslated region of encephalomyocarditis virus RNA directes internal entry of ribosomes during in vitro translation. J Virol 62:2636-2643.
89. Wouters BG, van den Beucken T, Magagnin MG, Koritzinsky M, Fels D, Koumenis C (2005) Control of the hypoxic response through regulation of mRNA translation. Semin Cell Dev Biol 16:487-501.
90. van der Velden AW, Thomas AA (1999) The role of the 5 ¢ untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 31:87-106.
91. Huez I, Bornes S, Bresson D, Creancier L, Prats H (2001) New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15:2197-2210.
92. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H (1998) Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 18:6178-6190.
93. Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52:43-47.
94. Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343-354.
95. Wang GL, Semenza GI (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237.
96. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible facotr 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631-32637.
97. Zhang P, Zhang X, Hao X, Wang Y, Hui Y, Wang H, Hu D, Zhou J (2009) Rac1 activated HIF-1 in retinal pigment epithelium cells under hypoxia. Graefes Arch Clin Exp Ophthalmol 247:633-639.
98. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M (2009) Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA 106:8760-8765.
99. Levy NS, Chung S, Furneaux H, Levy AP (1998) Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417-6423.
100. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331-371.
101. Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746-2753.
102. Fan XC, Steitz JA (1998) HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci USA 95:15293-15298.
103. Amadio M, Scapagnini G, Lupo G, Drago F, Govoni S, Pascale A (2008) PKCßII/HuR/ VEGF: a new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacol Res 57:60-66.
104. Iida K, Kawakami Y, Sone H, Suzuki H, Yatoh S, Isobe K, Takekoshi K, Yamada N (2002) Vascular endothelial growth factor gene expression in a retinal pigmented cell is up-regulated by glucose deprivation through 3 ¢ UTR. Life Sci 71:1607-1614.
105. Ozawa K, Tsukamoto Y, Hori O, Kitao Y, Yanagi H, Stern DM, Ogawa S (2001) Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmatic reticulum chaperone. Cancer Res 61:4206-4213.
106. Abcouwer SF, Marjon PI, Loper RK, Vander Jagt DL (2002) Response of VEGF expression to amino acid deprivation and inducers of endoplasmatic reticulum stress. Invest Ophthalmol Vis Sci 43:2791-2798.
107. Kase S, He S, Sonoda S, Kitamura M, Spee C, Wawrousek E, Ryan SJ, Kannan R, Hinton DR (2010) a B-crystallin regulation of angiogenesis by modulation of VEGF. Blood 115:3398-3406.
108. Deudero JJ, Caramelo C, Castellanos MC, Neria F, Fernandez-Sanchez R, Calabia O, Penate S, Gonzalez-Pacheco FR (2008) Induction of hypoxia-inducible factor 1 alpha gene expression by vascular endothelial growth factor. J Biol Chem 283:11435-11444.
109. Klettner A, Roider J (2008) Comparison of Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49:4523-4527.
110. Garrett TA, Van Buul JD, Burridge K (2007) VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp Cell Res 313:3285-3297.
111. Handa JT, Verzijl N, Matrsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, Miyata T, Hjemeland LM (1999) Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci 40:775-779.
112. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP (1998) Advanced glycation end products increases retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224.
113. Yokota T, Utsunomiya K, Taniguchi K, Gojo A, Kurata H, Tajima N (2007) Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol 51:424-430.
114. Ye X, Xu G, Chang Q, Fan J, Sun Z, Qin Y, Jiang AC (2010) Erk1/2 signaling pathways involved in VEGF release in diabetic rat retina. Invest Ophthalmol Vis Sci 51:5226-5233.
115. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836-43841.
116. Yanni SE, McCollum GW, Penn JS (2010) Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Exp Eye Res 91:34-41.
117. Madsen-Bouterse SA, Kowluri RA (2008) Oxidative stress and diabetic retinopathy:pathophysiological mechanism and treatments perspectives. Rev Endocr Metab Disord 9:315-327.
118. Ding X, Patel M, Chan CC (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28:1-18.
119. Hartnett ME (2010) The effects of oxygen stresses on the development of feature of severe retinopathy of prematurity: knowledge from 50/10 OIR model. Doc Ophthalmol 120:25-39.
120. Klettner A, Roider J (2009) Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases. Graefes Arch Clin Exp Ophthalmol 247:1487-1492.
121. Kannan R, Zhang N, Sreekumar P, Spee C, Rodriguez A, Barron E, Hinton D (2006) Stimulation of apical and basolateral vascular endothelial growth factor-A and vascular endothelial growth factor-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis 12:1649-1659.
122. 189 in choroidal endothelial cell transmigration in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 52:570-578.
123. Sreekumar P, Kannan R, de Silva A, Burton R, Ryan R, Hinton D (2006) Thiol regulation of vascular endothelial growth factor-A and its receptors in human retinal pigment epithelial cells. Biochem Biophys Res Commun 346:1200-1206.
124. Platt DH, Bartoli M, El-Remessy AB, Al-Shabrawey M, Lemtalsi T, Fulton D, Caldwell RB (2005) Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic Biol Med 39:1353-1361.
125. Al-Shabrawey M, Bartoli M, El-Remessy AB, Ma G, Matragoon S, Lemtalsi T, Caldwell RW, Caldwell RB (2008) Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 49:3231-3238.
126. Caldwell RB, Zhang W, Romero MJ, Caldwell RW (2010) Vascular dysfunction in retinopathy- an emerging role for arginase. Brain Res Bull 81:303-309.
127. Nagineni CN, Kommineni VK, Willian A, Detrick B, Hooks JJ (2012) Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 227(1):116-126.
128. Yingchuan F, Chuntao L, Hui C, Jianbin H (2010) Increased Expression of TGF-beta1 and Smad 4 on oxygen-induced retinopathy in neonatal mice. Adv Exp Med Biol 664:71-77.
129. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, Hooks JJ (2003) Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol 197:453-462.
130. Wilkinson-Berka JL, Wraight C, Werther G (2006) The role of growth homone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem 13:3307-3317.
131. Economou MA, Wu J, Vasilcanu D, Rosengren L, All-Ericsson C, van der Ploeg I, Menu E, Girnita L, Axelson M, Larsson O, Seregard S, Kvanta A (2008) Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Acta Ophthalmol 86:42-49.
132. Weng CY, Kothary PC, Verkade AJ, Reed DM, Del Monte MA (2009) MAP kinase pathway is involved in IGF-1-stimulated proliferation of human retinal pigment epithelial cell (hRPE). Curr Eye Res 34:867-876.
133. Cordeiro S, Seyler S, Stindl J, Milenkovic VM, Strauss O (2010) Heat-sensitive TRPV channels in retinal pigment epithelial cells: regulation of VEGF-A secretion. Invest Ophthalmol Vis Sci 51:6001-6008.
134. Salimen A, Kauppinen A, Hyttinen JMT, Toropainen E, Kaarniranta K (2010) Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization. Mol Med 16:535-542.
135. Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF (2004) Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 279:14844-14852.
136. Lucas N, Naiv AJ, Day ML (2009) The therapeutic potential of ADAM15. Curr Pharm Des 15:2311-2318.
137. Xie B, Shen J, Dong A, Swaim M, Hackett SF, Wyder L, Worpenberg S, Barbieri S, Campochiaro PA (2008) An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. FASEB J 22:2775-2783.
138. Surace EM, Balaggan KS, Tessitore A, Mussolino C, Cotugno G, Bonetti C, Vitale A, Ali RR, Auricchio A (2006) Inhibition of ocular neovascularisation by hedgehog blockade. Mol Ther 13:573-579.
139. He H, Zhang H, Li B, Li G, Wang Z (2010) Blockade of the sonic hedgehog signalling pathway inhibits choroidal neovascularization in a laser-induced rat model. J Huazhong Univ Sci Technolog Med Sci 30:659-665.
140. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Gyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Study Group (2004) Pepagtanib for neovascular age-related macular degeneration. N Eng J Med 351:2805-2816.
141. 165. Proc Natl Acad Sci USA 102:18902-18907.
142. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R (2000) The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83:63-68.
143. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng G, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599.
144. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of Ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-870.
145. Kim KH, Li B, Houck K, Winer J, Ferrara N (1992) The VEGF proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64.
146. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C (2006) Structurefunction studies of two synthetic anti-VEGF Fabs and comparison with Avastin Fab. J Biol Chem 281:6625-6631.
147. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N (2008) Interaction between Bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49:522-527.
148. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Qarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425-430.
149. Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS (2009) Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 26:295-320.
150. Miura Y, Klettner A, Roider J (2010) VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione. Invest Ophthalmol Vis Sci 51:4848-4855.
151. Klettner A, Möhle F, Roider J (2010) Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 248:819-824.
152. Klettner AK, Kruse ML, Meyer T, Wesch D, Kabelitz D, Roider J (2009) Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 247:1601-1608.
153. Spitzer MS, Yoeruek K, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 245:1837-1842.
154. Brar VS, Sharma RK, Murthy RK, Chalam KV (2010) Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal gangion cells. Mol Vis 16:1848-1853.
155. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tübingen Bevacizumab Study Group, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitrial injection of bevacizumab. Am J Ophthalmol 143:995-1002.
156. Muller YA, Chen Y, Christinger HW, Cunningham BC, Lowman HB, de Vos AM (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6:1153-1167.
157. Holash J, Davis S, Papadopoulos N, Croll S, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe W, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 99:11393-11398.
158. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, Papadopoulos N, Pyles EA, Torri A, Wiegand SJ, Thurston G, Stahl N, Yancopoulos GD (2007) VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104:18363-18370.
159. Dixon JA, Oliver S, Olson JL, Mandava N (2009) VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drug 18:1573-1580.
160. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Cell Biol 4:457-467.
161. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularisation in a mouse model. Mol Vis 9:210-216.
162. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA (2006) Suppression of ocular neovascularisation with siRNA targeting VEGF receptor 1. Gene Ther 13:225-234.
163. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozika M, Barri JZ, Albuquerque RJ, Yamasaki S, Itava M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Kariko K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597.
164. Kaiser PK, Symons RCA, Shah SM, Quinlan EJ, Tabendeh H, Do DV, Reisen G, Lockridge JA, Short B, Guerciolini R, Nguyen QD (2010) RNAi-based treatment for neovascular agerelated macular degeneration by Sirna-027. Am J Ophthalmol 150:33-39.
165. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen activated protein cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
166. Gotink KJ, Verheul HMW (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13:1-14.
167. Johnson LN (2009) Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 42:1-40.
168. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670.
169. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C, Hartzoulakis B, Nally J, Stewart M, Cheng L, Menon M, Tickner M, Djordjevic S, Driscoll PC, Zachary I, Selwood DL (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem 53:2215-2226.
170. Giordano RJ, Cardo-Vila M, Lahdentranth J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249-1253.
171. Giordano RJ, Cardo-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawke DH, Valente A, Almeida FCL, Nör JE, Sidman RL, Pasqualini R, Arap W (2010) From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci USA 107:5112-5117.
172. Nagpal M, Nagpal K, Nagpal PN (2007) A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 55:437-439.
173. Bian ZM, Elner SG, Elner VM (2007) Regulation of VEGF mRNA expression and protein secretion by TGF-ß2 in human retinal pigment epithelial cells. Exp Eye Res 84:812-822.
174. 165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma:balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98:1366-1379.
175. 165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 12:626-632.